Levocarnil

Levocarnitine, the active ingredient in Levocarnil, is a nutritional supplement presented as an injectable solution for intramuscular and intravenous use. It is employed to address primary and secondary carnitine deficiency and to support patients with metabolic disorders that benefit from carnitine supplementation.

GNH USA supplies Levocarnil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide through regulated distribution channels.

Levocarnil provides L‑carnitine supplementation for disorders of fatty‑acid metabolism.

Primary carnitine deficiency: restores intracellular carnitine levels to improve energy production. Secondary carnitine deficiency: replenishes carnitine lost due to renal disease, dialysis, or certain medications. Metabolic disorders requiring carnitine supplementation: supports β‑oxidation in inherited or acquired metabolic conditions.

Adverse reactions to Levocarnil are generally infrequent but may occur following intramuscular or intravenous administration.

Common Side Effects: - Nausea - Vomiting - Injection site pain - Flushing or warmth

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions - Hypotension or cardiovascular collapse - Seizures (rare) - Arrhythmias

Before using Levocarnil, consider the following precautions.

Assess renal function: adjust use in patients with severe renal impairment. Monitor for hypersensitivity: watch for rash, itching, or signs of anaphylaxis. Use cautiously in seizure‑prone patients: rare seizures have been reported. Avoid in individuals with known hypersensitivity to L‑carnitine or formulation excipients. Store at ambient temperature: keep in original container, protect from moisture and light.

Levocarnil may interact with other medicines; review the following.

Major Interactions (Avoid): - Valproic acid: may increase risk of hyperammonemia when combined with levocarnitine. - Warfarin: levocarnitine can potentiate anticoagulant effect, increasing bleeding risk. - High‑flux dialysis membranes: may remove administered carnitine, reducing efficacy.

Moderate Interactions (Monitor Closely): - Carbapenem antibiotics: can lower plasma carnitine concentrations, requiring monitoring. - Thyroid hormone therapy: may alter metabolic response to levocarnitine. - Concurrent nutritional supplements containing carnitine: risk of additive effects, monitor total intake.